Structure Therapeutics Inc.(GPCR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
GPCR Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Structure Therapeutics Inc. (GPCR), a Healthcare sector company. GPCR is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Structure Therapeutics Inc. reports net income of $-76.0M, free cash flow of $14.1M. Top institutional holders of GPCR by reported 13-F value include FMR, WELLINGTON MANAGEMENT GROUP LLP, Avoro Capital Advisors, based on the most recent SEC filings. GPCR trades on the Nasdaq exchange and files with the SEC under CIK 1888886. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GPCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Structure Therapeutics Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-76.0M
Free Cash Flow
Q1 2026
$14.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-36.7% YoYOperating Income
-54.0% YoYEPS (Diluted)
+3.7% YoYTotal Assets
+87.4% YoYOp. Cash Flow
-46.7% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Net Income | $-122.5M -36.7% | $-89.6M -74.6% | $-51.3M | — |
| Operating Income | $-158.2M -54.0% | $-102.8M -95.5% | $-52.6M | — |
| EPS (Diluted) | $-0.78 +3.7% | $-0.81 -61.7% | $-0.50 | — |
| Total Assets | $903.3M +87.4% | $482.0M +392.6% | $97.8M | — |
| Operating Cash Flow | $-116.6M -46.7% | $-79.5M -72.4% | $-46.1M | — |
AI Insight: GPCR Financial Trends
Equity surged to $1,516M in Q4 2025 — likely a capital raise — but operating losses deepened to -$89M by Q1 2026, the worst in the series.
• Operating losses have widened steadily from -$33M in Q2 2024 to -$89M in Q1 2026, indicating accelerating cash burn.
• Equity jumped from $770M in Q3 2025 to $1,516M in Q4 2025, suggesting a significant equity raise roughly doubling the balance sheet.
• Q4 2025 net income turned positive at $33M — a one-quarter anomaly — before reverting to -$76M in Q1 2026, consistent with a non-recurring item.
• Operating cash flow remains negative throughout, hitting -$64M in Q4 2025 and improving slightly to $15M inflow in Q1 2026.
⚠ Equity declined from $1,516M to $1,447M in one quarter — if burn continues at this pace, runway will erode rapidly.
⚠ No revenue reported across all eight quarters; any pipeline catalyst generating milestone or licensing income is a key inflection to track.
⚠ The Q1 2026 operating cash inflow of $15M despite a -$89M operating loss warrants scrutiny — working capital movements may be masking true burn.
AI Insight: GPCR Ratio Trends
ROIC swung from +6.3% in Q4 2025 back to -24.7% in Q1 2026, underscoring persistent capital destruction interrupted by a single profitable quarter.
• ROIC deteriorated steadily from -14.5% in Q2 2024 to -38.3% in Q3 2025, signaling deepening capital inefficiency over five consecutive quarters.
• Q4 2025 produced an anomalous reversal with ROE of 8.7%, ROA of 8.3%, and ROIC of 6.3% — the only profitable quarter in the dataset.
• Q1 2026 ROIC snapped back to -24.7%, and TTM ROIC stands at -14.5%, confirming the Q4 2025 gain was not sustained.
⚠ Nature of Q4 2025 profit spike warrants scrutiny — whether driven by milestone payment, asset sale, or operations determines reproducibility.
⚠ TTM ROE of -11.8% and ROA of -11.3% confirm ongoing equity and asset erosion; cash runway duration is a key monitoring point.
Get alerted when GPCR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Structure Therapeutics Inc. including:
Top Institutional Holders of GPCR
FMR LLC
$405.0M8,403,449 shWELLINGTON MANAGEMENT GROUP LLP
$349.9M7,260,287 shAvoro Capital Advisors LLC
$316.0M6,555,555 shDeep Track Capital, LP
$206.3M4,279,848 shBVF INC/IL
$166.7M3,459,358 shMORGAN STANLEY
$111.1M2,305,457 shPRINCIPAL FINANCIAL GROUP INC
$84.5M1,753,764 shDRIEHAUS CAPITAL MANAGEMENT LLC
$76.0M1,577,356 shORBIMED ADVISORS LLC
$71.1M1,475,403 shAMERICAN CENTURY COMPANIES INC
$69.3M1,438,031 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $405.0M | 8,403,449 |
| WELLINGTON MANAGEMENT GROUP LLP | $349.9M | 7,260,287 |
| Avoro Capital Advisors LLC | $316.0M | 6,555,555 |
| Deep Track Capital, LP | $206.3M | 4,279,848 |
| BVF INC/IL | $166.7M | 3,459,358 |
| MORGAN STANLEY | $111.1M | 2,305,457 |
| PRINCIPAL FINANCIAL GROUP INC | $84.5M | 1,753,764 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $76.0M | 1,577,356 |
| ORBIMED ADVISORS LLC | $71.1M | 1,475,403 |
| AMERICAN CENTURY COMPANIES INC | $69.3M | 1,438,031 |
More Healthcare Companies
View all Healthcare →Put GPCR on your watchlist
Track score changes the day Structure Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GPCR a good stock to buy?
13F Pro's AI-powered analysis of Structure Therapeutics Inc. (GPCR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GPCR are available on the GPCR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own GPCR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GPCR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Structure Therapeutics Inc.'s investment landscape.